The in vitro diagnostics (IVD) sector stands as a cornerstone of modern healthcare, empowering clinicians with the tools to detect diseases, monitor health conditions, and guide precise treatment decisions.
As healthcare evolves, the IVD market is poised for transformative growth. With the rising prevalence of chronic conditions such as diabetes and cardiovascular diseases, as well as ongoing threats from infectious diseases like COVID-19 and emerging variants, the demand for innovative diagnostic solutions has never been greater.
In Vitro Diagnostics Business Outlook is a bimonthly publication, delivering six issues annually, each dedicated to a different segment of the IVD industry. It provides exclusive insights and data, including:
Market Data and Forecasts: Detailed growth rates, market size, and market share to identify new opportunities.
Comprehensive Market View: Coverage of test categories and company profiles.
M&A Activities: Updates on mergers, acquisitions, partnerships, and collaborations.
Industry & Region Watch: Tailored strategies based on regional and industry-specific trends.
News Analysis: In-depth reporting on significant news and events, including exclusive information not readily available elsewhere.
Table of Contents
Volume 4, Issue 1 – Focus on Cardiac Biomarkers
Market Analysis: Cardiac Biomarker Testing
Overview of Cardiac Biomarkers
Market Outlook
Figure: Cardiac Marker Testing Market by End User, 2024-2029 ($ million) (Lab-based, POC-based)
Table: Cardiac Marker Diagnostic Sales by End User, 2024-2029 ($ million) (Lab-based, POC-based)
Figure: Cardiac Marker Testing Market by End User and Total Value Over Time, 2019-2029 ($ million) (Lab-based, PoC-based)
